Exact Mass: 373.15008480000006
Exact Mass Matches: 373.15008480000006
Found 160 metabolites which its exact mass value is equals to given mass value 373.15008480000006,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Olopatadine Hydrochloride
C21H24ClNO3 (373.14446240000007)
D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist D002491 - Central Nervous System Agents > D000700 - Analgesics D000893 - Anti-Inflammatory Agents D018501 - Antirheumatic Agents D018926 - Anti-Allergic Agents Olopatadine hydrochloride (ALO4943A) is a histamine blocker used to treat allergic conjunctivitis. Target: Histamine Receptor Olopatadine hydrochloride (ALO4943A) is one of the second-generation histamine H1 receptor antagonists that are treated for allergic disorders. Olopatadine hydrochloride (ALO4943A) significantly inhibited the ear swelling and the increased production of IL-4, IL-1beta, IL-6, GM-CSF and NGF in the lesioned ear [1]. Olopatadine hydrochloride (ALO4943A) was highly and rapidly absorbed in healthy human volunteers. The urinary excretion of Olopatadine hydrochloride (ALO4943A) accounted for not less than 58\% and the contribution of metabolism was considerably low in the clearance of olopatadine in humans. Olopatadine hydrochloride (ALO4943A) is one of the few renal clearance drugs in antiallergic drugs. Olopatadine hydrochloride (ALO4943A) was shown to be useful for the treatment of allergic rhinitis and chronic urticaria in double-blind clinical trials [2]. Olopatadine hydrochloride (ALO4943A) inhibits histamine release in a concentration-dependent fashion (IC50 = 559 microM) from human conjunctival mast cell preparations in vitro. Passive anaphylaxis in guinea pig conjunctiva was attenuated by Olopatadine hydrochloride (ALO4943A) applied 30 min prior to intravenous or topical ocular antigen challenge (ED50 values 0.0067\% and 0.0170\%, w/v, respectively) [3].
Clebopride
A - Alimentary tract and metabolism > A03 - Drugs for functional gastrointestinal disorders > A03F - Propulsives > A03FA - Propulsives D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents C78272 - Agent Affecting Nervous System > C66883 - Dopamine Antagonist D005765 - Gastrointestinal Agents > D000932 - Antiemetics D002491 - Central Nervous System Agents
diethyl 4-(4-hydroxy-3-methoxyphenyl)-2,6-dimethylpyridine-3,5-dicarboxylate
(E)-N-(4-hydroxy-3,5-dimethoxyphenethyl)-3-(4-hydroxy-3-methoxyphenyl)acrylamide|hibiscusamide
Cystodytin E
An alkaloid that is an enamide obtained by the formal condensation of tiglic acid with 6-(2-amino-1-hydroxyethyl)-4H-pyrido[2,3,4-kl]acridin-4-one. It is isolated from the Okinawan marine tunicate Cystodytes dellechiajei and exhibits cytotoxicity against human epidermoid carcinoma KB cells
(1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-(3-methyl-5-oxo-1-phenyl-1,5-dihydro-pyrazol-4-yliden)-amin|(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-(3-methyl-5-oxo-1-phenyl-1,5-dihydro-pyrazol-4-yliden)-amine|1,5,5-trimethyl-2,2-diphenyl-1,2,2,4-tetrahydro-4,4-azanylylidene-bis-pyrazol-3-one|Methylrubazonsaeure
Cystodytin D
An alkaloid that is an enamide obtained by the formal condensation of 3-methylbut-2-enoic acid with 6-(2-amino-1-hydroxyethyl)-4H-pyrido[2,3,4-kl]acridin-4-one. It is isolated from the Okinawan marine tunicate Cystodytes dellechiajei and exhibits cytotoxicity against human epidermoid carcinoma KB cells.
Gly Asn Pro Ser
Gly Asn Ser Pro
Gly Pro Asn Ser
Gly Pro Ser Asn
Gly Ser Asn Pro
Gly Ser Pro Asn
Asn Gly Pro Ser
Asn Gly Ser Pro
Asn Pro Gly Ser
Asn Pro Ser Gly
Asn Ser Gly Pro
Asn Ser Pro Gly
Pro Gly Asn Ser
Pro Gly Ser Asn
Pro Asn Gly Ser
Pro Asn Ser Gly
Pro Ser Gly Asn
Pro Ser Asn Gly
Ser Gly Asn Pro
Ser Gly Pro Asn
Ser Asn Gly Pro
Ser Asn Pro Gly
Ser Pro Gly Asn
Ser Pro Asn Gly
Clebopride
A - Alimentary tract and metabolism > A03 - Drugs for functional gastrointestinal disorders > A03F - Propulsives > A03FA - Propulsives D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents C78272 - Agent Affecting Nervous System > C66883 - Dopamine Antagonist D005765 - Gastrointestinal Agents > D000932 - Antiemetics D002491 - Central Nervous System Agents
2-[(1-Acetyl-2-oxopropyl)thio]-N-cyclohexyl-1H-benzimidazole-1-carboxamide
alpha-Hydroxy-alpha-phenylbenzeneacetic acid (3-endo)-8-azabicyclo[3.2.1]oct-3-yl ester hydrochloride
C21H24ClNO3 (373.14446240000007)
Sepimostat
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors C471 - Enzyme Inhibitor > C783 - Protease Inhibitor Sepimostat (FUT-187 free base) exhibits neuroprotective activity via NR2B N-methyl-D-aspartate receptor antagonism at the Ifenprodil-binding site of the NR2B subunit. Sepimostat inhibits the Ifenprodil binding with a Ki value of 27.7?μM[1].
4-(P-TOLUENESULFONYLAMINO)PHENYLBORONIC ACID PINACOL ESTER
C19H24BNO4S (373.15190140000004)
5-[bis(1-isocyanato-1-cyclohexa-2,4-dienyl)methyl]-5-isocyanato-cyclohexa-1,3-diene
N-(5-CHLORO-3-((4-(DIETHYLAMINO)-2-METHYLPHENYL)IMINO)-4-METHYL-6-OXOCYCLOHEXA-1,4-DIEN-1-YL)ACETAMIDE
4-methyl-N-[2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]benzenesulfonamide
C19H24BNO4S (373.15190140000004)
3-(Toluene-4-sulfonylaMino)phenylboronic acid, pinacol ester
C19H24BNO4S (373.15190140000004)
4-O-benzyl 2-O-ethyl 3-(2-ethoxy-2-oxoethyl)-5-methyl-1H-pyrrole-2,4-dicarboxylate
S1RA hydrochloride
S1RA (E-52862) hydrochloride is an orally active and selective sigma-1 receptor (σ1R) antagonist with a Ki value of 17 nM. S1RA hydrochloride shows good selectivity against σ2R (Ki >1000 nM). S1RA hydrochloride is a human 5-HT2B receptor antagonist with an IC50 value of 4.7 μM. S1RA hydrochloride inhibits neuropathic pain and activity-induced spinal sensitization[1][2].
(2S,4R)-1-(TERT-BUTOXYCARBONYL)-4-(4-(TRIFLUOROMETHYL)BENZYL)PYRROLIDINE-2-CARBOXYLIC ACID
C18H22F3NO4 (373.15008480000006)
(4s)-(-)-4,5-dihydro-2-[2-(diphenylphosphino)phenyl]-4-isopropyloxazole
(R)-(+)-2-[2-(Diphenylphosphino)phenyl]-4-isopropyl-2-oxazoline
Proroxan hydrochloride
C21H24ClNO3 (373.14446240000007)
C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs
6-methyl-2-[[(4-methylanilino)-oxomethyl]amino]-5,7-dihydro-4H-thieno[2,3-c]pyridine-3-carboxylic acid ethyl ester
4-(4-methoxycarbonylphenyl)-1,2,6-trimethyl-4H-pyridine-3,5-dicarboxylic acid dimethyl ester
1,3-diethyl-6-methyl-N-(2-methylphenyl)-2-oxo-5-benzimidazolesulfonamide
4-(3-hydroxyphenyl)-1-(2-oxolanylmethyl)-4H-pyridine-3,5-dicarboxylic acid dimethyl ester
1-[Tert-butyl-[(3,5-dimethylphenyl)-oxomethyl]amino]-3-(4-chlorophenyl)urea
3-methyl-N-{4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl}benzamide
4-[[3-oxo-2-(3-pyridinyl)-1H-isoindol-1-yl]amino]benzoic acid ethyl ester
butyl 4-[5-[(E)-(ethylcarbamothioylhydrazinylidene)methyl]furan-2-yl]benzoate
(2,6-Difluorophenyl)-[4-(5-fluoro-2-methyl-1-benzimidazolyl)-1-piperidinyl]methanone
4-[3-(1,3-Benzodioxol-5-ylmethylamino)-7-methyl-2-imidazo[1,2-a]pyridinyl]phenol
6-[[[1-(2-methoxy-5-methylphenyl)-5-tetrazolyl]thio]methyl]-N2,N2-dimethyl-1,3,5-triazine-2,4-diamine
N-[4-[2-methyl-4-(2-methylpropyl)-5-oxo-2-oxolanyl]-2-thiazolyl]benzohydrazide
3,5-dimethyl-4-[[(1R,5S)-7-[4-[(E)-prop-1-enyl]phenyl]-3,6-diazabicyclo[3.1.1]heptan-6-yl]sulfonyl]-1,2-oxazole
(4-fluorophenyl)-[(1R,5S)-7-[4-(3-pyridinyl)phenyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]methanone
[(2S,3S)-6-methylsulfonyl-3-phenyl-1-(2-pyridinylmethyl)-1,6-diazaspiro[3.3]heptan-2-yl]methanol
[(2S,3R)-1-methylsulfonyl-3-phenyl-6-(2-pyridinylmethyl)-1,6-diazaspiro[3.3]heptan-2-yl]methanol
2-[(1,5-Dimethyl-3-oxo-2-phenylpyrazol-4-yl)diazenyl]-3-(2-methylphenyl)-3-oxopropanenitrile
Osavampator
Osavampator (TAK-653) is a AMPA receptor positive allosteric modulator. Osavampator selectively binds to AMPA-R in a glutamate-dependent manner and induces Ca2+ influx in hGluA1i CHO cells (EC50 = 3.3 μM). Osavampator improves learning and memory in many models. Osavampator is can be used for the research of depressive disorders[1][2]. Osavampator (TAK-653) is a AMPA receptor positive allosteric modulator. Osavampator selectively binds to AMPA-R in a glutamate-dependent manner and induces Ca2+ influx in hGluA1i CHO cells (EC50 = 3.3 μM). Osavampator improves learning and memory in many models. Osavampator is can be used for the research of depressive disorders[1][2].
(3s,6e,8r,12s,14s)-5,7,9-trihydroxy-8-methyl-13,16-dioxa-4-azatetracyclo[15.2.2.1³,⁶.0¹²,¹⁴]docosa-1(19),4,6,17,20-pentaen-22-one
n-{6,13-dihydroxy-5,14,15-trimethoxytricyclo[9.4.0.0²,⁷]pentadeca-1(15),2,4,6,11,13-hexaen-8-yl}ethanimidic acid
(1s,11s,13s)-14,15-dimethoxy-20-methyl-5,7,21-trioxa-20-azahexacyclo[11.4.3.1¹¹,¹⁴.0¹,¹³.0²,¹⁰.0⁴,⁸]henicosa-2,4(8),9-trien-16-one
2-[4-(3-chloro-1h-pyrrol-2-yl)-3-methylbuta-1,3-dien-1-yl]-6-methoxy-3-methyl-5-(2-methylbut-3-en-2-yl)pyran-4-one
C21H24ClNO3 (373.14446240000007)
(1s,15r,17r,18s,19r)-18-(acetyloxy)-5,7-dioxa-12-azapentacyclo[10.6.1.0²,¹⁰.0⁴,⁸.0¹⁵,¹⁹]nonadeca-2,4(8),9-trien-17-yl acetate
(1s,13s,16s,17r)-16-(acetyloxy)-5,7-dioxa-12-azapentacyclo[10.5.2.0¹,¹³.0²,¹⁰.0⁴,⁸]nonadeca-2,4(8),9-trien-17-yl acetate
(1s,13s,15r,18r)-15-hydroxy-5,7-dioxa-12-azapentacyclo[10.5.2.0¹,¹³.0²,¹⁰.0⁴,⁸]nonadeca-2,4(8),9,16-tetraen-18-yl (3s)-3-hydroxybutanoate
(14r,16r)-14-hydroxy-16-isopropyl-15-oxa-2,12,18-triazahexacyclo[11.8.1.1¹⁴,¹⁸.0³,⁸.0⁹,²².0²¹,²³]tricosa-1,3(8),4,6,9(22),10,12,21(23)-octaen-17-one
[(1r,3r)-1-butyl-10-hydroxy-7-(methylamino)-6,9-dioxo-1h,3h,4h-naphtho[2,3-c]pyran-3-yl]acetic acid
9-(5-{[(1-hydroxy-3-methylbutylidene)amino]carbonyl}-4-oxopyran-2-yl)nona-2,4,8-trienoic acid
(3s,6z,8r,9s,12s,14s)-5,7,9-trihydroxy-8-methyl-13,16-dioxa-4-azatetracyclo[15.2.2.1³,⁶.0¹²,¹⁴]docosa-1(19),4,6,17,20-pentaen-22-one
16-oxoprometaphanine
{"Ingredient_id": "HBIN001950","Ingredient_name": "16-oxoprometaphanine","Alias": "NA","Ingredient_formula": "C20H23NO6","Ingredient_Smile": "CN1C(=O)CC23C1(CC(C4=C2C(=C(C=C4)OC)OC)O)C(=O)C(=CC3)OC","Ingredient_weight": "373.4 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "16401","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "91895298","DrugBank_id": "NA"}
14-hydroxy-16-isopropyl-15-oxa-2,12,18-triazahexacyclo[11.8.1.1¹⁴,¹⁸.0³,⁸.0⁹,²².0²¹,²³]tricosa-1,3(8),4,6,9(22),10,12,21(23)-octaen-17-one
(1r,8s,10s,11r)-11-hydroxy-3,4,12-trimethoxy-17-methyl-18-oxa-17-azapentacyclo[8.4.3.1⁸,¹¹.0¹,¹⁰.0²,⁷]octadeca-2,4,6,12-tetraen-16-one
methyl 2-[(3r)-3-[2-(dimethylamino)ethyl]-9-hydroxy-8-methoxy-1-oxonaphtho[1,2-c]furan-3-yl]acetate
n-[2-(4-hydroxy-3,5-dimethoxyphenyl)ethyl]-3-(4-hydroxy-3-methoxyphenyl)prop-2-enimidic acid
[1-butyl-10-hydroxy-7-(methylamino)-6,9-dioxo-1h,3h,4h-naphtho[2,3-c]pyran-3-yl]acetic acid
n-(2-hydroxy-2-{12-oxo-8,14-diazatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(17),2(7),3,5,8,10,13,15-octaen-10-yl}ethyl)-3-methylbut-2-enimidic acid
9,15-dimethoxy-5,7-dioxa-12-azapentacyclo[10.5.2.0¹,¹³.0²,¹⁰.0⁴,⁸]nonadeca-2,4(8),9,16-tetraen-18-yl acetate
{15-methoxy-5,7,19-trioxa-12-azapentacyclo[10.5.3.0¹,¹³.0²,¹⁰.0⁴,⁸]icosa-2,4(8),9,16-tetraen-18-yl}methyl acetate
(1s,17s,18s,19s)-17-hydroxy-5,7-dioxa-12-azapentacyclo[10.6.1.0²,¹⁰.0⁴,⁸.0¹⁵,¹⁹]nonadeca-2,4(8),9,15-tetraen-18-yl (3s)-3-hydroxybutanoate
3-hydroxy-4,11,12-trimethoxy-17-methyl-17-azatetracyclo[8.4.3.0¹,¹⁰.0²,⁷]heptadeca-2,4,6,11-tetraene-13,16-dione
(2e)-n-[2-(4-hydroxy-3,5-dimethoxyphenyl)ethyl]-3-(4-hydroxy-3-methoxyphenyl)prop-2-enimidic acid
8-hydroxy-3,4,12-trimethoxy-17-methyl-17-azatetracyclo[8.4.3.0¹,¹⁰.0²,⁷]heptadeca-2,4,6,12-tetraene-11,16-dione
(14s,16s)-14-hydroxy-16-isopropyl-15-oxa-2,12,18-triazahexacyclo[11.8.1.1¹⁴,¹⁸.0³,⁸.0⁹,²².0²¹,²³]tricosa-1,3(8),4,6,9(22),10,12,21(23)-octaen-17-one
(2e,4e,8e)-9-(5-{[(1-hydroxy-3-methylbutylidene)amino]carbonyl}-4-oxopyran-2-yl)nona-2,4,8-trienoic acid
(2e)-n-(2-hydroxy-2-{12-oxo-8,14-diazatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(17),2(7),3,5,8,10,13,15-octaen-10-yl}ethyl)-2-methylbut-2-enimidic acid
2,3-dihydroxy-4-[4-(2-{[hydroxy(phenyl)methylidene]amino}ethyl)phenoxy]-2-methylbutanoic acid
(1s,15r,17s,18s,19r)-17-(acetyloxy)-5,7-dioxa-12-azapentacyclo[10.6.1.0²,¹⁰.0⁴,⁸.0¹⁵,¹⁹]nonadeca-2,4(8),9-trien-18-yl acetate
(1r,13r,15r,18r)-9,15-dimethoxy-5,7-dioxa-12-azapentacyclo[10.5.2.0¹,¹³.0²,¹⁰.0⁴,⁸]nonadeca-2,4(8),9,16-tetraen-18-yl acetate
16-(acetyloxy)-5,7-dioxa-12-azapentacyclo[10.5.2.0¹,¹³.0²,¹⁰.0⁴,⁸]nonadeca-2,4(8),9-trien-17-yl acetate
14,15-dimethoxy-20-methyl-5,7,21-trioxa-20-azahexacyclo[11.4.3.1¹¹,¹⁴.0¹,¹³.0²,¹⁰.0⁴,⁸]henicosa-2,4(8),9-trien-16-one
n-[1-hydroxy-3-(4-hydroxy-3-methoxyphenyl)propan-2-yl]-3-(4-hydroxy-3-methoxyphenyl)prop-2-enimidic acid
methyl 2-{3-[2-(dimethylamino)ethyl]-9-hydroxy-8-methoxy-1-oxonaphtho[1,2-c]furan-3-yl}acetate
(1r,8s,10s)-8-hydroxy-3,4,12-trimethoxy-17-methyl-17-azatetracyclo[8.4.3.0¹,¹⁰.0²,⁷]heptadeca-2,4,6,12-tetraene-11,16-dione
(1r,13r,15r,18s)-9,15-dimethoxy-5,7-dioxa-12-azapentacyclo[10.5.2.0¹,¹³.0²,¹⁰.0⁴,⁸]nonadeca-2,4(8),9,16-tetraen-18-yl acetate
(2e)-n-[(2r)-1-hydroxy-3-(4-hydroxy-3-methoxyphenyl)propan-2-yl]-3-(4-hydroxy-3-methoxyphenyl)prop-2-enimidic acid
2-[(1e,3e)-4-(3-chloro-1h-pyrrol-2-yl)-3-methylbuta-1,3-dien-1-yl]-6-methoxy-3-methyl-5-(2-methylbut-3-en-2-yl)pyran-4-one
C21H24ClNO3 (373.14446240000007)